Lynk Pharmaceuticals Co. Ltd.

Suzhou Sinovent Pharmaceuticals Co., Ltd.

Hangzhou Rex Pharmaceutical Co., Ltd.

Yujun Gao

Jian Wu

Xiaodong Li

Dong Wang

Ximing Shen

Yaodong Wu

Yonghui Wang

Juan Zhou

Binbin Hong

Chunqi Li

Zhaokui Wan

Tao Liu

Michael Lawrence Vazquez

Yan Zhu

Shiqun Wang

Wandeng Liu

Provided in the present disclosure is crystal form I of compound 1, and a preparation method thereof and the use thereof.

Crystal form of pyrazolyl-amino-pyrimidinyl derivative, and preparation method therefor and use thereof

A five-membered heterocyclic amide WNT pathway inhibitor having the following general structural formula: The five-membered heterocyclic amide WNT pathway inhibitor has a remarkable anti-tumor activity based on a target-based rational drug design, and can be used for the development of a new generation of Wnt pathway inhibitors, and has a great clinical application value and considerable market potential.

Five-membered heterocyclic amides WNT pathway inhibitor

The present invention discloses a compound for regulating protein kinase activity and used for treating or preventing diseases associated with protein kinases. Specifically, the present invention relates to a benzofuran pyrazole amine protein kinase inhibitor which belongs to compounds that regulate anaplastic lymphoma kinase (ALK), and provides a method of preparing such a compound and a pharmaceutical use of such a compound in the treatment or prevention of diseases associated with ALK. The inhibitor can solve the problem of the drug resistance of the first generation and the second generation of ALK inhibitors.

Benzofuran pyrazole amine kinase inhibitor

Growing community of inventors

Zhejiang, China

Yujun Gao